Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MJ Gleeson delivers upbeat outlook despite H1 profit decline

(Sharecast News) - Construction group MJ Gleeson saw profits fall sharply in the first half but delivered a confident outlook on the back of a strong pick-up in housing reservations in January. Total revenues across the six months to 31 December were up 4.2% year-on-year at £157.9m, with Gleeson Homes growing 10% to £156.6m. The company sold 801 homes during the period, up from 769 the year before, while the average selling prices increased by 4.8% to £193,900.

The Gleeson Land division saw revenues slump 86% to £1.3m after no land sales were completed during the period. However, after restructuring operations, the company is confident that it will continue to grow its portfolio of sites in the second half and beyond.

Group operating profits were down 42% at £5.1m mainly due to a lack of completed sales by Gleeson Land.

Looking ahead, MJ Gleeson said it was seeing "encouraging signs of a recovery in demand" with reservation rates rising strongly in January. The positive start to the second half means the board is confident in meeting market expectations for the full year, it said.

"At Gleeson Homes, there are early indications of an improving selling season with much stronger net reservation rates in the first four weeks. More importantly, we are pleased with the progress of our site opening programme which will drive sustained growth over the medium-term," said chief executive Graham Prothero.

Shares were up nearly 2% at 501p by 0950 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.